Invion Stock

Invion FCF Growth

The Year-over-Year Free Cash Flow Growth of Invion (IVX.AX) as of Sep 4, 2026 is 10.07 %. In the previous year, Year-over-Year Free Cash Flow Growth was 24.77 % — a change of -59.34% (lower).

FCF Growth

10.07 %

YoY

-59.34%

Last updated:

Year-over-Year Free Cash Flow Growth of Invion is 2026 10.07 % . Year-over-Year Free Cash Flow Growth of Invion was 2025 24.77 % . It decreases by -59.34% lower compared to the previous year.

The Invion FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2018
386.16 AUD
Jan 1, 2019
-398.66 AUD
Jan 1, 2020
92.78 AUD
Jan 1, 2021
374.10 AUD
Jan 1, 2022
-2,099.74 AUD
Jan 1, 2023
47.50 AUD
Jan 1, 2024
24.77 AUD
Jan 1, 2025
10.07 AUD
The Invion FCF Growth history
YEARFCF GrowthYoY
10.07 %-59.34%
24.77 %-47.85%
47.50 %-102.26%
-2,099.74 %-661.28%
374.10 %+303.22%
92.78 %-123.27%
-398.66 %-203.24%
386.16 %+312.78%
93.55 %+48.33%
63.07 %-150.81%
-124.13 %—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Year-over-Year Free Cash Flow Growth of Invion is 10.07 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Invion since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Growth — Invion

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Invion